About Us

Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprietary technologies, we are developing a robust pipeline of AXC candidates with the potential to address unmet medical needs for new treatment options.

Our Technology

Management

Zou Bin, Ph.D.

Chief Executive Officer
Founder

Zhong Chen

SVP Biology

Bryan Yeung

VP Chemistry

Tan Ban Xiong

Director, Antibody

Scientific Advisory Board

Paul Herrling

Kyriacos Costa Nicolaou

Board of Directors

Zou Bin, Ph.D.

Chairman

Jack Yin Zheng, Ph.D.

Board Member

Thomas Keller, Ph.D.

Board Member